Rare Diseases market is projected to grow at a CAGR of 8.8% by 2034: Visiongain
June 06, 2024 12:50 ET
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Rare Diseases Market Report 2024-2034: Forecasts by Diseases (Cancer, Metabolic Diseases, Neurological Conditions, Hematologic Disorders, Infectious...
Gene Therapy R&D market is projected to grow at a CAGR of 29.8% by 2034: Visiongain
June 06, 2024 12:41 ET
|
Visiongain Reports Ltd
Visiongain has published a new report entitled Gene Therapy R&D Market Report 2024-2034: Forecasts by Disease (Cancer, Rare Diseases (Oncologic, Non-oncologic), Cardiovascular Diseases, Ophthalmic...
Active Pharmaceutical Ingredient Market is Expected to Reach $238.3 billion | MarketsandMarkets™
June 06, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, June 06, 2024 (GLOBE NEWSWIRE) -- Active Pharmaceutical Ingredient market in terms of revenue was estimated to be worth $163.5 billion in 2024 and is poised to reach $238.3 billion by 2029,...
Ipsen nomme Josep Catllà, en qualité de Vice-Président Exécutif, Chief Corporate Affairs Officer
June 06, 2024 08:30 ET
|
Ipsen Pharma
PARIS, FRANCE, 06 juin 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de spécialité, annonce aujourd’hui la nomination de Josep Catllà en tant que Vice-Président...
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
June 06, 2024 08:30 ET
|
Ipsen Pharma
PARIS, FRANCE, 06 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Josep Catllà as EVP, Chief Corporate Affairs...
Global Vaccines (Monovalent, Multivalent) Market Research Report 2024-2028: $94.9 Billion Market Analysis by Technology, Disease, Route of Administration
June 05, 2024 04:25 ET
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease...
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
June 04, 2024 07:00 ET
|
CytoSorbents
CTSO STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024
FutureBrand Consumer Index Reveals Brands Are Missing Key Growth Opportunities and Falling Short on Relevance
June 04, 2024 06:00 ET
|
FutureBrand
Unveiled today, the FutureBrand Launches The FutureBrand Consumer Index, revealing how brands are missing key growth opportunities.
Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]
June 03, 2024 16:15 ET
|
Sanofi - Aventis Groupe
ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients atteints d’un myélome multiple...
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
June 03, 2024 16:15 ET
|
Sanofi - Aventis Groupe
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in...